Investigators reviewed cases of patients with multiple sclerosis treated with alemtuzumab to determine the type and frequency of thyroid dysfunction.
First trimester exposure to anytithyroid drugs was associated with a greater risk of congenital malformations, especially for pregnant women who were given prescriptions for methimazole or both methimazole and propylthiouracil.
Patients given teprotumumab were more likely to experience a response at 24 weeks vs placebo.
In a randomized, double-blind study, Rituximab was more effective in treating Graves' orbitopathy than intravenous methylprednisolone.
Statins and thyroidectomy may delay or prevent thyroid-associated ophthalmopathy in Graves' disease.
Thyroid-specific autoantibody levels did not predict clinical features of Graves' disease, including ophthalmopathy or goiter.
Women should likely discontinue methimazole during pregnancy to prevent complications.
Rituximab did not perform better than a placebo in treating Graves' orbitopathy in a randomized controlled trial.
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Hypothyroidism Treatment No Longer Available
- Endocrine-Disrupting Chemicals in Personal Care Products Linked to Early Puberty
- Normalized HbA1c Levels Facilitate Improved Neuropathy Outcomes in T2D
- Hypertensive Disorders in Pregnancy, Postpartum BMI Linked to T2D Risk
- Sleep Quality, Duration Affect Risk for Falls and Fractures in Older Women
- Physician Burnout Linked to Stress in Using Health Information Technology
- Type 2 Diabetes Linked to Colorectal Cancer Risk in Men
- Urinary Incontinence Drug May Reduce Frequency of Hot Flashes